Table 1.
Clinical progression in “pre-MCI” subjects with pathophysiological biomarkers positivity.
| Reference | Group (N) | Mean Follow-Up | Biomarker Assessed | % Biomarkers+ (N) | % Progress (N) | Clinical Progression |
|---|---|---|---|---|---|---|
| Dubois et al. 2018 [73] | SMC (318) | 2 years | Amyloid PET | 28% (88) | 5% (4) | MCI |
| Donohue et al. 2017 [74] | CN (445) | 3.1 years | Amyloid PET | 45% (202) | 32% (71) | MCI |
| Wolfsgruber et al. 2017 [32] | SCD (82) | 2.3 years | CSF | 24% (20) * | 65% (13) | MCI/dementia |
| Van Harten et al. 2013 [75] | SCC (132) | 1.5 years | CSF | 7% (10) * | 60% (6) | MCI/dementia |
| Van Harten et al. 2013 [76] | SCC (127) | 3.9 years | CSF | 7% (10) * | 50% (5) | MCI/dementia |
CN: cognitively normal; CSF: cerebrospinal fluid; MCI: Mild Cognitive Impairment; PET: Positron Emission Tomography; SCD: subjective cognitive decline; SCC: subjective cognitive complaints; SMC: subjective memory complaints. * abnormal Aβ42 + abnormal tau and/or p-tau.